BioAffinity Technologies

11/25/2025

Congratulations, Dr. Rodriguez!

11/19/2025

Since April 2024, Dr. Sai Karan Vamsi Guda has incorporated CyPath® Lung into his practice:
“For patients with small pulmonary nodules, six millimeters or larger, we utilize CyPath® Lung to be able to risk stratify them.”

Want to learn how CyPath® Lung can support your practice? Reach out to admin@bioaffinitytech.com

11/14/2025

We continued to see rapid growth and meaningful progress in Q3 2025:
⚫️CyPath® Lung volumes up 97% YTD
⚫️ Record Q3 sales, up 92% from Q2
⚫️ Testing revenue up 122% YoY
⚫️ New U.S. patent issued for our diagnostic algorithm
⚫️Raised $10.4M to support operations and growth
⚫️Returned to full Nasdaq Capital Market compliance
⚫️Added Roberto Rios, CPA, and John J. Oppenheimer, M.D., to our Board
“Our focus on expanding CyPath® Lung adoption, especially within the VA, is delivering results,” said CEO Maria Zannes.
Read the full announcement on our website ➡ https://bit.ly/3JDLBcS

11/11/2025

Honoring Our Veterans

Today, we honor the courage and sacrifice of those who have served our nation. At bioAffinity Technologies, we observe Veterans Day by reaffirming our commitment to helping Veterans live longer and healthier lives through early detection of lung cancer. CyPath® Lung is now available to Veterans through the VA health system.

11/08/2025

Lung cancer is still the leading cause of cancer deaths globally. Yet fewer than 1 in 5 people eligible for low-dose CT (LDCT) screening actually get screened.
US guidelines recommend LDCT screening for smokers and former smokers at risk for developing lung cancer. Annual screening can reduce the lung cancer death rate by up to 20% by detecting tumors at early stages.
At bioAffinity Technologies, we’re advancing noninvasive diagnostics like CyPath® Lung, designed to help physicians detect lung cancer early, when treatment is most effective and lives can be saved.
On Day, we join clinicians and advocates nationwide to raise awareness about lung cancer screening and improve accessibility to lifesaving LDCT screening.

11/07/2025

Best of luck to our VP of Sales, Dallas Coleman, as he represents CyPath® Lung in Charlotte, NC, at the Society for Advanced Bronchoscopy’s 2025 Pitch Party!
We’re honored to have Dallas share how CyPath® Lung is helping advance early detection and diagnosis in lung health.

11/06/2025

November is
Lung cancer is the leading cause of cancer death worldwide, yet early detection can make all the difference.
Lung cancer doesn’t just affect smokers. Anyone with lungs can be at risk. Many people don’t realize that up to 20% of those diagnosed have never smoked. Understanding the risks, and the importance of screening is key to saving lives.
At bioAffinity Technologies, we’re committed to advancing awareness and improving early detection through innovative science, including our noninvasive test, CyPath® Lung.
This month, we stand with patients, families, and healthcare providers working toward a future where lung cancer is found early and treated effectively.

11/05/2025

This , we’re happy to see continued strong momentum in the marketplace for CyPath® Lung, our noninvasive diagnostic aiding in early lung cancer detection.
October test volume rose 111% above the 2025 monthly average, reflecting steady physician adoption and growing clinical trust.
Learn more: https://bit.ly/4qL5v6h

10/21/2025

Day 2 at ! We're continuing great conversations with clinicians and researchers about advancing noninvasive lung diagnostics.
Stop by Booth 2242 to learn how CyPath® Lung uses flow cytometry and to support earlier, more accurate detection of lung cancer.

10/20/2025

Exciting week at ! Visit us at Booth 2242.

Dr. Rossella Titone is presenting new research showing how our sample handling methods help make CyPath® Lung a reliable, noninvasive test for detecting early-stage lung cancer.
We’re proud to have Dr. Gordon Downie, our Chief Medical Officer, and Dr. Titone and Dr. David Elzi from our R&D group at CHEST to share how science and innovation are helping catch lung cancer when it’s most treatable.

10/20/2025

CHEST 2025 is underway.

10/17/2025

AI is changing how we diagnose cancer - delivering earlier and less invasive detection that can lead to treatment and longer, healthier lives. The U.S. Patent Office issued its intention to award bioAffinity Technologies a patent for our AI-built algorithm and flow cytometry platform to detect lung cancer. Harnessing AI with our novel flow cytometry platform has resulted in a test that produces high-precision, standardized, data-driven results to guide physicians on next steps in care for patients at high risk for lung cancer.

The US Patent and Trademark Office will issue BIAF a new patent on its flow cytometry+AI platform that detects lung cancer as early as Stage 1A.